Alnylam Pharmaceuticals: Challenges In The TTR Space And Few Late-Stage Catalysts Are A Concern [Seeking Alpha]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Seeking Alpha
ALNY's TTR franchise outperformed rivals in Q3, but prescription growth and competitive pricing dynamics remain key investor watchpoints. Competition is intensifying, yet none have demonstrated superior efficacy to Amvuttra; market expansion and underdiagnosis offer long-term growth runway. Valuation appears attractive near $500/share sum-of-parts, making ALNY a potential 'buy the dip' candidate if share price weakness continues. nopparit/E+ via Getty Images The last three months have been a little more challenging for Alnylam Pharmaceuticals ( ALNY ), with slowing sales at a key rival raising concerns about the overall health of the critical transthyretin amyloidosis (or TTR) space, particularly with This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of ALNY, RHHBY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation f
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Leerink Partners from $370.00 to $351.00. They now have a "market perform" rating on the stock.MarketBeat
- Lululemon Set to Exit Nasdaq 100 as Index Adds New Members [Yahoo! Finance]Yahoo! Finance
- Alnylam, Seagate among six stocks added to Nasdaq-100 in annual rebalance [Seeking Alpha]Seeking Alpha
- 200% Surge? These 6 Stocks Just Crashed the Nasdaq 100 Party [Yahoo! Finance]Yahoo! Finance
- Annual Changes to the Nasdaq-100 Index® [Yahoo! Finance]Yahoo! Finance
ALNY
Earnings
- 10/30/25 - Beat
ALNY
Sec Filings
- 12/11/25 - Form 8-K
- 12/3/25 - Form 8-K
- 12/1/25 - Form 4
- ALNY's page on the SEC website